Axsome Therapeutics, Inc.
AXSM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 10.40 | 1.31 | 1.15 | -0.92 |
| FCF Yield | 0.02% | -0.63% | -0.76% | -0.64% |
| EV / EBITDA | -129.39 | -119.18 | -98.42 | -56.49 |
| Quality | ||||
| ROIC | -12.14% | -9.72% | -16.03% | -21.28% |
| Gross Margin | 93.03% | 91.04% | 91.94% | 91.15% |
| Cash Conversion Ratio | -0.02 | 0.68 | 0.73 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 35.94% | 39.46% | 44.04% | 97.54% |
| Free Cash Flow Growth | 104.31% | 25.25% | -65.35% | -41.94% |
| Safety | ||||
| Net Debt / EBITDA | 2.37 | 2.06 | 1.61 | 1.74 |
| Interest Coverage | 41.17 | -20.02 | -23.44 | -10.45 |
| Efficiency | ||||
| Inventory Turnover | 0.50 | 0.73 | 0.60 | 0.67 |
| Cash Conversion Cycle | -126.66 | -370.54 | -517.92 | -374.02 |